Shares of biotech company Clene (NASDAQ:CLNN) are tanking today after its lead product candidate CNM-Au8 failed to meet the primary endpoint in amyotrophic lateral sclerosis (ALS) trial.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
ALS is a rare neurological condition.
Is CLNN Stock a Buy?
Despite the ~56.3% slide in CLNN price so far this year, the Street sees a massive 541.03% potential upside in the stock based on an average price target of $12.50.
Further, the stock has a Strong Buy consensus rating based on three unanimous Buys.
Read full Disclosure
